Predict your next investment

HEALTHCARE | Medical Facilities & Services / Medical Practice Management & Services

See what CB Insights has to offer


Unattributed | Alive

Total Raised


Last Raised

$30K | 11 yrs ago

About DigiPath

DigiPath provides advisory services to healthcare service providers with digital pathology solutions providing improved patient care, exceeding return on investment goals, eliminating any operational inefficiencies and providing a means for the firm to stay competitive.

DigiPath Headquarter Location

2360 Corporate Cir Suite 400

Henderson, Nevada, 89074,

United States

Latest DigiPath News

13:07 ET EVIO Inc. Executes Letter of Intent to sell C3 Labs, LLC to Digipath, Inc.

Dec 7, 2021

. News provided by Share this article Share this article HENDERSON, Nev., Dec. 7, 2021 /PRNewswire/ -- EVIO, Inc. announced today that it intends to sell its ownership in C3 Labs, LLC dba Steep Hill CA to Digipath, Inc. (OTCQB: DIGP ) in exchange for assumption of debt and stock in Digipath. This sale marks the company's next step towards EVIO's restructuring plans which began in January 2021. The sale of C3 Labs means that the company will be able to divest over $2 million in debt and future lease obligations and gain a yet to be disclosed equity stake in Digipath. Interim CEO Lori Glauser says "This sale gives C3 Labs the investment it needs to achieve profitability without EVIO taking on more debt. It also gives EVIO an investment stake in the growing lab company while substantially reducing operating costs." EVIO continues to operate its labs in Canada and Oregon. Furthermore, the company is planning a roll-out its blockchain technology offerings during first quarter 2022. About EVIO EVIO, Inc. is a provider of ancillary services including consulting, R&D and analytical testing for cannabis, hemp, and pharmaceutical companies. For more information, visit and Safe Harbor Statement Any statements in this press release that are not statements of historical fact may be considered forward-looking statements pertaining to anticipated or projected plans, performance, and developments, as well as other statements relating to future operations and results. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only, and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, the Company's ability to complete product testing and launch product commercially, the acceptance of product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in Company reports filed with the Securities and Exchange Commission and OTC Markets, available at or . For Further Information contact:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.